Medicine Becomes Monetized

August 24, 1998

San Francisco, Calif. -- In the 1990s, the practice of medicine has become the cost-effective provision of health care services, rather than a matter of curing the sick, according to Penn State researchers.

"Medicine has become monetized, which is not necessarily all good or all bad," says Dr. Mark W. Dirsmith, professor of accounting in Penn State's Smeal College of Business Administration.

The old question asked of patients entering a hospital emergency room was, "Where does it hurt?" followed by "Are you insured?" Today's question is "What type of insurance do you have?"

"Doctors are being transformed from physical professionals to fiscal decision makers," says Dirsmith. "The field is also very crowded with shadow people -- insurance people, employee benefits people."

At for-profit hospitals, doctors no longer make decisions based on the diagnosed illness and the available medical knowledge, drugs and technology. They now must consider who is going to pay for whatever treatment is prescribed and make decisions in consultation with HMO personnel.

"One good is that cost containment has been achieved," Dirsmith told attendees today (Aug. 24) at the American Sociological Association meeting in San Francisco. "However, it is the progressive hospitals that benefit."

He notes that the poor, the underinsured, the old and the young are going to hospitals that are not profit-based, perhaps not as progressive or up-to-date, but are more willing to provide service.

On the other hand, consolidation and economy in medicine has led to the proliferation and availability of very expensive, high technology tools for treatment and diagnosis, such as CAT scans and MRIs.

The researchers, who include Dirsmith, Dr. Sajay Samuel, assistant professor of accounting at Bucknell University and Dr. Barbara McElroy, assistant professor of accounting at Berry College, suggest that the advent of HMOs is not the sole cause of this shift in medical care, and cutting out HMOs is not the answer. The advent of the speaking patient and the general acceptance that health can be maintained have helped to shift medical practice.

"No longer will a patient sit quietly while a doctor treats them," says Samuel. "The patients want to know what is wrong with them, what will be done to them, what the potential consequences are and what they can do to mitigate the situation."

The era of physician as god has ended. But the era of patients taking responsibility for controlling their blood pressure, cholesterol, weight and general well being is not necessarily a bad thing.

"Some companies are encouraging employees to jump on an illness sooner, rather than later," says Dirsmith. "Especially at firms where there is low turnover, there is a growing humanitarian concern for the employee."

But the monetization of medicine brings with it some negatives that the researchers view as dehumanizing. The hospital as factory is a new phenomenon.

"Some hospitals now specialize in cancer treatment, or in treating hernias," says Samuel. "The body is being divided into parts, subsystems upon which to work, rather than curing a person."

Part of the blame for this is placed on DRGs -- diagnosis related groups -- a set of procedures and practices that represent a predictable amount of costs. According to the researchers, DRGs were originally created at the request of physicians to help them evaluate what took place in hospitals. Today, there are currently 470 DRGs, and DRGs have spread around the world and place patients into categories like vaginal delivery without complications or simple pneumonia and pleurisy age greater than 17.

"DRGs convert the patient to an object and the body into a collection of organs and systems," says Dirsmith, the Penn State researcher.

This classification system converts medicine into a product that can be handled with all the tools of economics and standard business evaluations.

"Doctors, nurses, insurers and patients are all caught up within this new logic of medicine to function as providers and consumers of care, as sub-systems in a medico-economic system," says Dirsmith of Penn State

EDITORS: Dr. Dirsmith is at (814) 865-3904 or eu3@psu.edu by email; Dr. Samuel is at (814) 867-1638 or sxs26@psu.edu by email.
-end-


Penn State

Related Cancer Treatment Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

A new treatment for liver cancer
In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

NUS researchers show potential liver cancer treatment by targeting cancer stem-like cells
NUS researchers from the Cancer Science Institute of Singapore and the N.1 Institute for Health have shown the potential use of small molecule inhibitors to treat advanced liver cancer.

Breast cancer gene a potential target for childhood liver cancer treatment
Hepatoblastoma is a rare liver cancer that mainly affects infants and young children and is associated with mutations in the β-catenin gene.

Light therapy could replace opioids as main treatment for cancer treatment side effect
A worldwide coalition of researchers and clinicians has agreed that light therapy is among the most effective interventions for the prevention of oral mucositis, painful ulcers in the mouth resulting from cancer therapy.

Scanning for cancer treatment
11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019.

Visualizing better cancer treatment
Researchers have engineered nanoscale protein micelles capable of both delivering chemotherapeutic drugs and of being tracked by MRI.

Read More: Cancer Treatment News and Cancer Treatment Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.